Industry News and Headlines

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

CRISPR Therapeutics shares rose over 12% after reporting Q4 2025 earnings that showed a larger‑than‑expected loss and minimal recognized revenue. The company’s flagship therapy CASGEVY generated $54 million in sales, but under its revenue‑sharing deal with Vertex only $0.86 million was recorded. CRISPR holds about $1.9 billion in cash, giving a three‑to‑four‑year runway while it advances pipeline candidates such as CTX611 for anticoagulation. Analysts remain cautious, maintaining a Hold rating with a modest price target, suggesting the stock is better suited for long‑term investors.